NCT06955858View on ClinicalTrials.gov

Clinical Study of rhTPO in Hematopoietic Stem Cell Mobilization for Autologous Transplantation in Acute Leukemia

NANot yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 30, 2025

Primary Completion Date

July 30, 2026

Study Completion Date

December 30, 2026

Conditions
Hematopoietic Stem Cell Mobilization
Interventions
DRUG

Recombinant Human Thrombopoietin（rhTPO）

"G-CSF will be administered at a dose of 10 μg/kg/day subcutaneously for 7-10 days post-chemotherapy.~rhTPO is started on the same day as G-CSF at 300 U/kg/d and injected subcutaneously until the stem cell collection was completed."

Trial Locations (1)

Unknown

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER

NCT06955858 - Clinical Study of rhTPO in Hematopoietic Stem Cell Mobilization for Autologous Transplantation in Acute Leukemia | Biotech Hunter | Biotech Hunter